Using a broader , more inclusive definition of adverse effects , these still were lower in PREVAIL ( Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy ) trial than in PROTECT AF ( 4.2 % vs. 8.7 % ; p = 0.004 ) .